<DOC>
	<DOCNO>NCT02053181</DOCNO>
	<brief_summary>The study investigate pharmacokinetics , safety , tolerability cadazolid subject severe Clostridium difficile diarrhea ( CDAD ) whether influence quantity cadazolid absorb systemic circulation .</brief_summary>
	<brief_title>Study Investigate Pharmacokinetics Safety Cadazolid Patients With Clostridium Difficile Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Signed informed consent prior studymandated procedure . Nonpregnant female remain nonpregnant 1 month end study . Female subject childbearing potential must negative serum pregnancy test screening must use reliable method contraception Subjects severe CDAD ; Clostridium difficile infection ( CDI ) must microbiologically prove , use validate enzymelinked immunosorbent assay ( ELISA ) detection C. difficile toxin A ( TcdA ) and/or C. difficile toxin B ( TcdB ) . The severity CDAD assess accord current European Union guideline European Society Clinical Microbiology Infectious Diseases ( ESCMID ) . Received oral vancomycin oral/intravenous ( i.v . ) metronidazole therapy treatment CDAD . Ability communicate well investigator local language , understand comply requirement study . Known hypersensitivity excipients drug formulation . Clinical evidence relevant disease CDAD and/or existence surgical medical condition might interfere absorption , distribution , metabolism excretion study drug . Veins unsuitable i.v . puncture either arm ( e.g. , vein difficult locate , access , puncture ; vein tendency rupture puncture ) . Subjects rare hereditary fructose intolerance , glucosegalactose malabsorption , saccharaseisomaltase deficiency previously undiagnosed diabetes mellitus . Subjects lifethreatening condition , may relate CDAD underlie illness . Any clinically relevant electrocardiogram ( ECG ) abnormality screen . Subjects unable swallow difficulty swallow . Subjects vomit , ileus pass stool . Likelihood death within 72 hour cause . Lifethreatening fulminant CDAD ( White blood cell count &gt; 30 × 10^9/L ; temperature &gt; 40 °C ; septic shock , peritoneal sign significant dehydration ) . History ulcerative colitis Crohn 's disease . Loss 250 mL blood within 3 month prior screen . Positive result hepatitis serology , except vaccinated subject , screen . Positive result human immunodeficiency virus ( HIV ) serology screen . Legal incapacity limit legal capacity screen . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Cadazolid</keyword>
	<keyword>ACT-179811</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>